The advent of ultra-sensitive troponin testing has led to changes in the way the test is applied and has led to the discovery of many “troponin positive” illnesses that are not due to coronary artery disease.
This conundrum has prompted the medical profession to adopt important changes in the clinical definition of MI and means that the insurance industry currently has many in-force critical illness (CI) products that use an MI definition that differs from current clinical practice.
In this session, Dr. Nick Boon, RGA’s Consulting Medical Officer, U.K., and clinical cardiologist, discusses how MI is currently defined and present best practices to adjudicate borderline MI CI claims.
